Scilex Holding Company Announces Launch of Gloperba, the First Liquid Colchicine for Painful Gout Flares, Priced at $595 per Bottle
In an exciting development for gout sufferers, Scilex Holding Company has announced plans to launch Gloperba, the first liquid colchicine formulation for the prophylaxis of painful gout flares. Set to be available in the first half of 2024, Gloperba provides a much-needed alternative for patients with chronic kidney disease and gastrointestinal sensitivity, who require lower doses of colchicine than the standard tablet or capsule form.
Gout is a type of arthritis caused by the buildup of uric acid crystals in the joints, leading to severe pain, inflammation, and swelling. It is estimated that over 70% of gout patients also have chronic kidney disease, complicating treatment options. Due to the reduced kidney function in these patients, they require lower doses of medications to avoid severe toxicity.
Colchicine, an effective medication for gout management, is commonly prescribed at a standard dose of 0.6 mg. However, this dosage may be too high for individuals with renal impairment, necessitating a more precise and lower dosage. Gloperba fills this crucial gap in the market by offering healthcare providers the ability to prescribe precision dosing for at-risk patient populations.
With its unique formulation, Gloperba allows healthcare providers to safely and effectively manage gout patients at doses below the standard 0.6 mg. Patients treated with lower doses will benefit from a 150 ml bottle of the liquid colchicine formulation, which is expected to last for more than 30 days. This not only delivers additional value to patients by providing a more cost-effective option but also helps mitigate the risk of severe toxicity associated with higher doses in vulnerable individuals.
Scilex Holding Company’s commitment to non-opioid pain management products aligns with the ongoing efforts to find safer alternatives to address the opioid crisis. By focusing on developing and commercializing innovative pain management therapies, the company is filling critical gaps in the market and offering patients alternative treatment options.
In addition to the launch of Gloperba, Scilex Holding Company has been actively involved in sharing its research at prestigious medical conferences. The company recently announced the acceptance of an abstract for poster and oral presentation at the 2024 Annual Meeting of the American Academy of Pain Medicine (AAPM). This participation demonstrates Scilex’s commitment to advancing the field of pain management and staying at the forefront of scientific research.
Looking ahead to 2024, Scilex Holding Company’s Chief Executive Officer and President, Jaisim Shah, expressed optimism for the company’s future. In a letter to stockholders, Shah highlighted the accomplishments in 2023, including the successful development and commercialization of non-opioid pain management products. With the launch of Gloperba and the ongoing focus on innovative solutions, the company is well-positioned for continued growth and success in the coming year.
As gout sufferers eagerly anticipate the availability of Gloperba, this groundbreaking liquid colchicine provides hope for more effective and precise pain management. The launch of this innovative product marks a significant step forward in addressing the unique needs of gout patients with chronic kidney disease and gastrointestinal sensitivity. With its lower dosage options and extended supply, Gloperba promises to deliver improved outcomes and greater value to patients struggling with this debilitating condition.
Comments